Comparative Pharmacology
Head-to-head clinical analysis: ENOVID versus OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID versus OVRAL.
ENOVID vs OVRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Norethynodrel: 5-12 hours; mestranol: 7-20 hours. Terminal half-life of ethinyl estradiol from mestranol conversion: 10-30 hours. Clinical context: steady-state achieved after 3-5 half-lives (3-5 days).
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Renal (30-50% as metabolites, <5% unchanged) and fecal (40-60% via bile, mostly as glucuronide conjugates).
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive